60x12 tablets 500mg $300 (canadian dollars)
This product is available in tablets. Every bottle contains 60 tablets of 500 mg
.
This product is available in tablets. Every bottle contains 60 tablets of 500 mg
.
Here are some components written on the bottle for each tablet: extract of saw palmetto 160 mg, standardized for to contain 45% of fat acids (72 mg), Pygeum Africanum (with similar effects of Saw Palmetto) 50 mg with 2.5% of Betasitosterolo, Stinging Nettle (Urtica dioica) 120 mg, Green Tea Extract 110 mg with 50% of polifenoli and 30% of catechine, magnesium stereate 5 mg, Opt-zinc 10 mg, vitamin b6 50 mg.
Proguard is a good natural mix of component working against 5-alfa-reductase and ANTIANDROGEN. And it has a low price.
Please, read also Remox (hair regrowth product with minoxidil 12.5%, Retin-A ® (marchio registrato) 0.025% and hydrocortisone 0.01%), Revivogen, Hairloss (androgenetic alopecia) therapy and Top 5 hairloss treatments.
Proguard (tablet) is a complete natural product specifically developed to fight the effects of thinning hair (male / female-pattern baldness). Its formulation is based on a great deal of scientific research which firmly establishes the link that many natural agents have on combating the effects of dihydrotestosterone (DHT) in the treatment of benign prostatic hypertrophy (BPH).
It’s a natural alternative product or a good addition to Propecia, available low price.
Proguard (in tablet form) can also be used as a non-drug alternative of benign prostatic hypertrophy, the swelling of the prostate in middle-aged men.
The manufacturing house suggests to assume two capsules a day.
Proguard is not good for women in pregnancy, and for kids.
The product, in BASE of saw palmetto, has antiandrogen effects, similar to finasteride, in fact it can stop alpha-reductase of testosterone, the CITOSILIC receptor of DHT, as well as the estrogen citosilic receptor.
Proguard has been studied to stop hair loss and to provoke regrowth, annulling or decreasing possible collateral effects (even if in low percentage), in fact Propecia is without doubt the most effective.
A bottle of 60 capsules is enough for one month of tratment. I take one tablet of natural anti DHT a day added to one capsule of Propecia. Percentage of insuccessful is decreased.
Proguard (shampoo) is a complete natural product specifically developed to combat the effects of thinning hair (male/female pattern hair loss). Proguard shampoo combines deep cleaning agents, Proactive’s protected formula and the most powerful natural anti-dht fatty acids agents available. Proguard (shampoo) used daily stimulates and helps to restore the destructive effects of DHT on the hair follicle, and makes your weakened hair stronger and thicker.
Proguard (nightly anti-dht Topical Activator Serum) combines Minoxidil with natural oils, fatty acids and herbals which penetrate the scalp and carry the active ingredients to the hair follicle where. These active ingredients are all potent inhibitors of 5-Alpha-Reductase and, by reducing DHT production, help to revitalize and to block the miniaturization of the hair follicle.
PROSTATE DISEASE
The prostate is a gland located beneath the urinary bladder in men. It is responsible of the production of fluids involved in reproduction. When men urinate, the urine stored in the bladder travel through a conduit, called urethra, before it can exit out of penis. The urethra passes through the prostate after exiting the bladder. This is because the urethra is also responsible of the carriage of the reproductive fluids produced in the prostate. As a consequence of its location, an enlarged prostate can contribute to urinary flow obstruction as well as to bladder dysfunction by "squeezing" on the urethra. A symptom associated to an enlarged prostate is a frequent urination, increased urination at night, dribbling, a weak urinary stream, urgency, and incomplete emptying of the bladder. It can also result in the inability to urinate.
The medical term for an enlarged prostate, not related to cancer, is benign prostatic hypertrophy. This condition is thought, in part, from exposure to specific androgens, such as dihydrotestosterone.
Men after a certain age develop in this condition. Note that individuals born with a deficiency in 5 alpha-reductase, the enzyme that produces dihydrotestosterone, suffer neither hair loss nor prostatic disease. Individuals who lack this enzyme are unable to produce the more potent form of testosterone, dihydrotestosterone. Dihydrotestosterone (DHT) is required for the development of both androgenic alopecia (male/female pattern hair loss) and prostatic disease.
Treatment
There are two basic treatment options for an enlarged prostate gland or benign prostatic hypertrophy. These include medical (drugs) and surgical therapy. When men with benign prostatic hypertrophy, a condition that many physicians believe to be caused by excess dihydrotestosterone, were treated with oral or systemic finasteride (the generic name Propecia and Proscar), their enlarged prostate glands became smaller. Unfortunately, this study also demonstrated that a small percentage of the patients (less than 6%) receiving this drug also suffered from sexually related side effects such as decreased sex drive and impotence. Surgical therapy can also lead to sexually related side effects.
Recently, medical literature has provided increased support for the use of naturally occurring nutrients that prevent the progressive enlargement of the prostate gland (BPH). Some of these nutrients have even been demonstrated to reduce the incidence of prostate cancer! These nutrients that combat the detrimental effects of DHT in the prostate can be utilized to combat the effects of DHT in hair loss. The following discussion outlines multiple DHT fighting agents. These agents are included in Patented Proguard formulas.
Stinging nettle (Urtica dioica) is another herb indigenous to the United States. In addition to prostate disease, this herb has been utilized in Germany for the treatment of Rheumatoid Arthritis. This herb has been studied in combination with saw palmetto and pygeum africanum in the treatment of BPH. When used with saw palmetto, improvement with prostate related urinary problems was documented [1]. When combined with pygeum africanum, this herb was also demonstrated to prevent symptoms related to BPH. Researchers believe that this herb's mechanism of action affects the delivery of hormones to the prostate gland.
Green Tea extract is a
bioflavonoid-rich potent extract which is effective in the treatment of 5
alpha-dihydrotestosterone-dependent abnormalities, such as benign prostate hyperplasia,
prostate cancer and certain skin diseases.
It has been shown in
previous studies on Zinc that combined with b6, it was able to inhibit the conversion of
testosterone to DHT in the skin.
Zinc is a necessary
dietary mineral. Recent studies have shown that Zinc can inhibit DHT in the skin, leading
to the reduction of oil and helping hair regrow.
ESSENTIAL
FATTY ACIDS – (shampoo and activator)
Proguard contains
essential fatty acids found in plant oils and Minoxidal. These acids have been
individually shown to inhibit DHT, and are very effective in combating thinning hair
(male-female pattern hair loss). These acids gently remove DHT and
buildup from the scalp skin. They also protect and rejuvenate hair follicles.
CONCLUSION
After these About natural agents that reduce the effects of DHT on the prostate,the conclusion is that Proguard is a complete patent natural product specifically developed to combat the effects of androgenic alopecia (i.e., male/female-pattern baldness). Its product formulations are based on a great deal of medical research which firmly establishes that these natural agents can combat the effects of dihydrotestosterone (DHT) in the treatment of benign prostatic hypertrophy (BPH). Many studies have shown that DHT is responsible of male/female-pattern baldness and benign prostate enlargement, so Proguard will be useful for both conditions. And, these natural agents produce virtually no side effects. All the ingredients in the products have been scientifically tested and proven to reduce the effects of DHT and the conversion of testosterone to DHT which is the main cause of hair loss and benign prostate.
Proguard
Activator
Bottle - 8 oz/237 ml
Proguard Shampoo
Bottle - 1 OZ
Developed for men and women to help with thinning hair, Proguard Activator serum is a topical solution containing Proguard's patented ingredients. Using daily this product it can offset the effects of (DHT) that is known to cause male/female pattern hair loss.
Other similar products are: Bio-Organics Saw Palmetto Complex, Prostaguard, Hairgenesis Hair Revitalizing Formulation and Spencer Forrest Anti-Androgenic Hair Growth Complex.
Proguard is a treatment specifically developed to combat the effects of Androgenic Alopecia also known as male / female pattern hair loss. Its formualtion is based on a great deal of medical research which firmly establishes that the agents used in Proguard can combat the effects of Dihydrotesterone(DHT), which is known as one of the main causes of pattern hair loss in men and women.
Established Peer Scientific References
Dallob Al, et al. - J Clin Endocrinol Metab. 1994 Sep;79(3):703.
Sudduth SL et al. - Pharmacotherapy. 1993 Jul-Aug;13(4):309.
Puerto Am et al. - Rev Esp Fisiol. 1990 Sep;46(3):289-96.
Caballero MJ, et al. - Rev Esp Fisiol. 1990 Sep;46(3):283-8.
Sawaya ME et al. -J Invest Dermta. 1989 Jan;92(1):91-5.
Moltz L. - Geburtshilfe Frauenheilkd. 1988 Apr;48(4):203-14.
Caballero MJ, et al. - Rev Esp Fisiol. 1987 Jun;43(2):229-37
Wilt TJ, et al. -Jama. 1998 Nov 11;280(18):1604-9
Miller LG. - Arch Inter Med. 1998 Nov 9; 158(20):2200-11
Gerber GS. Et al. -Urology. 1998 Jun;51(6):1300-7
Harv Health Lett. 1998 May;23(7):6
Van Berkel GJ, et al. -Anal Chem. 1998 Apr 15;70(8):1544-44
Powers JE. - S D J Med. 1997 Dec;50(12):453-4
Shimada H et al. -J Nat Prod. 1997 Apr;60(4):417-8
Bracher F. Urologe A. 1997 Jan;36(1):10-7. Review
Dreikon K. et al -Urologe A. 1995 Mar;34(2):119-29 Review
Day JF et al -J Med Entomol. 1991 Jan;28(1):19-23
Breza J, et al. -Curr Med Res Opin. 1998;14(3):127-39
Yablonsky F et al. -J Urol. 1997 Jun;157(6):2381-7
Levin Rm, et al. -Eur Urol. 1997;32 Suppl 1:15-21
Dagues F et al. -Rev Prat. 1995 Feb 1;45(3):337-41. Review
Mathe G et al. -Biomed Pharmacother. 1995;49(7-8):341-3
Mathe G et al. -Biomed Pharmacother. 1995;49(7-8):339-40
Paubert-Braquet M et al. -J Lipid Mediat Cell Signal. 1994
Krzeski T et al. -Clin Ther. 1993 Nov-Dec;15(6):1011-20
Carini C et al. -Arch Ital Urol Nefrol Androl. 1991 Sep;63(3)
Barlet A et al. -Wien Klin Wochenschr. 1990 Nov23;102(22)
Menchini-Fabris GF et al. -Arch Ital Urol Nefrol Androl. 1998
Bassi P, et al. -Minerva Urol Nefrol. 1987 Jan-Mar;39(1):45-50
Clavert A, et al. -Ann Urol (Paris) 1986;20(5):341-3 French
Dufour B et al -Ann Urol (Paris). 1984 May 18(3):193-5 French
Longo R et al. -Farmaco (Prat) 1983 Jul;38(7):287-92
Pierini N, et al. -Boll Chim Farm. 1982 Jan;121(1):27-34.
Casella G. et al. -Arch Sci Med (Torino). 1978 Jan-Mar;135(1)
Thiebolt L. et al. -Therapie. 1977 Jan-Feb;32(1):99110.
Thieblot L. et al. - Therapie. 1971 May-Jun;26(3):575-80.
Dubois B, et al. -FEBS Lett. 1998 May 8;427(2):275-8
Schottner M et al. -Planta Med 1997 Dec;63(6):529-32
Ziyat A, et al. -J Ethnopharmacol. 1997 Sep;58(1):45-54
Lichius JJ, et al. - Planta Med 1997 Aug;63(4):307-10
Siebert HC, et al. - Glycocnj J. 1997 Jun;14(4):531-4
Sibert HC, et al. -Proteins. 1997 Jun;28(2):268-84
Vahlensieck W Jr. et al. -Fortschr Med 1996 Nov 10;114
Teucher T. et al. -Arzneimittelforschung. 1996 Sep;46(9):906-10
Musette P. et al. - Eur J Immunol. 1996 Aug 26(8):1707-11
Obertreis B, et al. -Arzneimittelforschung. 1996 Apr;46(4):
Delcourt M et al. Cell Immunol 1996 Mar 15;168(2):158-64
Musett P, et al. - Eur J Immunol 1196 Mar;26(3):618-22
Basaran AA et al. -Teratog Carcinog Mutagen 1996;16(2):125
Obertreis B. et al. -Arzneimittelforschung 1996 Jan;46(1):52-6
Zanglis A et al. -Int J Biochem Cell Biol. 1996 Jan;28(1):63-74
Davidov MI et al. -Urol Nefrol (mosk). 1995 Sep-Oct(5):19-20
Kayser K et al. - Anal Quant Cytol Histol. 1995 Apr;17(2):135
Hom K et al. -Febs Lett 1995 Mar 20;361(2-3):157-61
Galelli A et al. -J Immunol 1995 Mar 15;154(6):2600-11
Hyrb DJ et al. -Planta Med. 1995 Feb;61(1):31-2
Gansser D et al. -Z Naturforsch © 1995 Jan-Feb;50(1-2):98-104
Hirano T. et al. -Plant Med. 1994 Feb;60(1):30-3
Krzeski T. et al. -Clin Ther. 1993 Nov-Dec;15(6):-20
Iseli B et al. -Plant Physiol. 1993 Sep;103(1):221-6
Galelli et al J Immunol 1993 Aug 15;151(4):1821-31
Pusztai A et al. -Br J Nutr. 1993 Jul;70(1):313-21
Lerner Dr. et al. - J Biol Chem. 1992 Nov 5;267(31):22694
Le Moal Ma et al. -Res Immunol 1992 Sep;143(7):701-9
Le Moal et al. -Res Immunol. 1992 Sep;143(7):691-700
Lerner Dr et al. -J biol Chem 1992 Jun 5;267(16):11085-91
Balzarini J et al. -Antiviral Res. 1992 Jun;18(2):191-207
Beintema JJ, et al. -Febs Lett. 1992 Mar 9;299(2):131-4
Roman Ramos R et al. -Arch Med Res. 1992 Spring;23(1):59
De Bolle MF et al. -Electrophoresis. 1991 Jun;12(6):442-4
Oliver F et al. -Clin Exp Dermatol. 1991 Jan;16(1)1-7
Mittman P. -Planta Med 1990 Feb;56(1):44-7
Wagner H et al. -Planta Med 1989 Oct;55(5):452-4 German
Krivenko VV et al. - Vrach Delo 1989 Mar;(3)76-8 Russian
Swanston-Flatt Sk et al. -Diabetes Res. 1989 Feb;10(2):69-73
Le Moal Ma et al. -Cell Immunol. 1998 Aug;115(1):24-35
Wieringa Pa et al -Am J Physiol 1988 Apr;254(4 pt 2):h636-50
Shibuya N et al. -Arch Biochem Biophys 1986 Aug 15;249
Traas Ja et al. -J Cell Sci. 1985 Jun;76:303-20
Smallman Bn et al. -Biochem J.1981 Jan 15;194(1):361-4
Piekos R et al. -Plant Med. 1976 Dec;30(4):331-6
Radunz A. - Z Naturforsch {c} 1976 Sep-Oct;31(9-10):589-93
Oxford GS. -Heredity (Edinburgh) 1975 Dec;35(3):361-70
Shiina H et al. - Prostate.1996 Sep;29(3):169-76
Shiina H et al. - Br J Urol 1996 Jan;77(1):96-101
Fahim MS et al -Andrologia. 1993 Nov-Dec;25(6):369-75
Habib FK et al. - Urol Res. 1992;20(4):281-4
Hudson RW. - J Steroid Biochem . 1987 Mar;26(3):349-53
Suesum MO, et al. -J Androl. 1985 Jan-Feb;6(1)10-4
Lahtonen R. -Prostate. 1985;6(2):177-83
Singuim G et al. -J Steroid Biochem. 1984 Mar;20(3):773-80
Bermudez JA et al. - Arch Androl. 1982 Sep;9(2):167-9
Exaire E et al. -Arch Androl. 1982 Sep;9(2):183-7
Paniagua R et al.-Arch Androl. 1982 Jun;8(4):271-5
Terracio L et al. -Prostate. 1982;3(2):183-91
Netter A. et al. Arch Androl. 1981 Aug;7(1):69-73
Habib FK et al. --J Endrocrinol. 1976 Oct;71(1):133-41
